FI20115870A0 - Neuroprotective cell penetrating peptides - Google Patents
Neuroprotective cell penetrating peptidesInfo
- Publication number
- FI20115870A0 FI20115870A0 FI20115870A FI20115870A FI20115870A0 FI 20115870 A0 FI20115870 A0 FI 20115870A0 FI 20115870 A FI20115870 A FI 20115870A FI 20115870 A FI20115870 A FI 20115870A FI 20115870 A0 FI20115870 A0 FI 20115870A0
- Authority
- FI
- Finland
- Prior art keywords
- peptides
- seq
- disease
- amino acids
- penetrating peptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to the fields of bioactive peptides and cell-penetrating peptides as well as to the field of neurotrophic factors, i.e. growth factors for neural cells. The present invention provides peptides with length of 4 to 40 amino acids comprising the sequence CKGC (SEQ ID NO:1 ) or CRAC (SEQ ID NO:2). Pharmaceutical compositions comprising said peptides are also provided as well as the peptides for use in the treatment of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke, peripheral neuropathy, epilepsy, diabetes or drug addiction. The invention is also directed to a method for promoting survival of dopaminergic neurons. In addition, peptides with length of 4 to 40 amino acids comprising the sequence CXXC (SEQ ID NO: 5) for use in the above mentioned diseases are also provided.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20115870A FI20115870A0 (en) | 2011-09-05 | 2011-09-05 | Neuroprotective cell penetrating peptides |
PCT/FI2012/050859 WO2013034805A1 (en) | 2011-09-05 | 2012-09-05 | Neuroprotective cell-penetrating peptides |
EP12830062.1A EP2753641A4 (en) | 2011-09-05 | 2012-09-05 | Neuroprotective cell-penetrating peptides |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20115870A FI20115870A0 (en) | 2011-09-05 | 2011-09-05 | Neuroprotective cell penetrating peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
FI20115870A0 true FI20115870A0 (en) | 2011-09-05 |
Family
ID=44718780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI20115870A FI20115870A0 (en) | 2011-09-05 | 2011-09-05 | Neuroprotective cell penetrating peptides |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2753641A4 (en) |
FI (1) | FI20115870A0 (en) |
WO (1) | WO2013034805A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015508155A (en) | 2012-01-24 | 2015-03-16 | ユニバーシティ オブ マサチューセッツ | Soluble MANF in pancreatic beta cell injury |
WO2014191630A2 (en) * | 2013-05-28 | 2014-12-04 | Helsingin Yliopisto | Non-human animal model encoding a non-functional manf gene |
EP3113788A4 (en) | 2014-03-05 | 2017-10-18 | Lawrence M. Schwartz | Methods and compositions for the protection of sensory cells |
WO2015149005A1 (en) * | 2014-03-28 | 2015-10-01 | Buck Institute For Research On Aging | Methods and compositions for modulating the immune system |
US20170157243A1 (en) * | 2014-06-24 | 2017-06-08 | University Of Massachusetts | MANF as a Regulator of Immune System Function |
EP3377089B1 (en) | 2015-11-18 | 2020-04-08 | Herantis Pharma Plc | Compositions comprising cdnf for use in the intranasal treatment of central nervous system diseases |
MX2019013157A (en) | 2017-05-04 | 2020-08-03 | Helsingin Yliopisto | C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof. |
SG11202009341TA (en) | 2018-03-29 | 2020-10-29 | Helsingin Yliopisto | C-terminal cdnf fragments, pharmaceutical compositions comprising same and uses thereof |
EP3838912A1 (en) | 2019-12-20 | 2021-06-23 | Herantis Pharma Oyj | Retro-inverso peptides |
EP3838345A1 (en) | 2019-12-20 | 2021-06-23 | Herantis Pharma Oyj | Macrocyclic peptides |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043693A1 (en) * | 1998-02-26 | 1999-09-02 | Human Genome Sciences, Inc. | 36 human secreted proteins |
EP1265582A2 (en) * | 1999-09-29 | 2002-12-18 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
US20030109457A1 (en) * | 2001-10-25 | 2003-06-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
WO2002074956A2 (en) * | 2001-03-20 | 2002-09-26 | Prescient Neuropharma Inc. | Dopaminergic neuronal survival-promoting factors and uses thereof |
CA2441327A1 (en) * | 2001-03-30 | 2002-10-10 | Geneprot, Inc. | Human arginine-rich protein-related compositions |
EP2412719A1 (en) * | 2002-12-02 | 2012-02-01 | Xenome Ltd | Chi-conotoxin peptides |
ATE480559T1 (en) * | 2005-12-14 | 2010-09-15 | Licentia Ltd | USES OF A NEUROTROPHIC FACTOR |
FI20080326A0 (en) * | 2008-04-30 | 2008-04-30 | Licentia Oy | Neurotrophic factor MANF and its uses |
-
2011
- 2011-09-05 FI FI20115870A patent/FI20115870A0/en not_active Application Discontinuation
-
2012
- 2012-09-05 EP EP12830062.1A patent/EP2753641A4/en not_active Withdrawn
- 2012-09-05 WO PCT/FI2012/050859 patent/WO2013034805A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP2753641A1 (en) | 2014-07-16 |
WO2013034805A1 (en) | 2013-03-14 |
EP2753641A4 (en) | 2015-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI20115870A0 (en) | Neuroprotective cell penetrating peptides | |
MX359516B (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition. | |
AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
NZ703341A (en) | Compositions comprising apomorphine and organic acids and uses thereof | |
NZ621868A (en) | Growth hormone polypeptides and methods of making and using same | |
NZ621196A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
MX2013013833A (en) | Compositions, uses and methods for treatment of metabolic disorders and diseases. | |
TN2014000109A1 (en) | Fusion proteins for treating metabolic disorders | |
NZ611878A (en) | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides | |
MX2012001194A (en) | Antigenic tau peptides and uses thereof. | |
CY1112241T1 (en) | Peptide Fragments for Stimulating Protein Extracellular Matrix Synthesis | |
MX2012002502A (en) | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids. | |
EA201491155A1 (en) | NEW MUTANT PRO-NRF AND THEIR APPLICATION TO GET BETA-NRF | |
UY33222A (en) | Amino acid sequences directed against TRAIL cell surface receptor 2, compounds, constructs and effective variants | |
UA113962C2 (en) | PHARMACEUTICAL COMPOSITION CONTAINING APOMORPHINE AS AN ACTIVE INGREDIENT | |
MX2013010910A (en) | Neuroprotective peptides. | |
UA107836C2 (en) | Treatment of alzheimer's disease | |
EA201290856A1 (en) | STABILIZED PHARMACEUTICAL COMPOSITION | |
NZ590469A (en) | Treatment of rheumatoid arthritis with human beta defensins (1-4) | |
RU2492163C2 (en) | Cinnamic acid compounds (versions), intermediate compounds for their obtaining, based on them pharmaceutical composition, method of inhibiting histone diacetase, method of treating diabetes, method of treating tumour or disease associated with cell proliferation, method of enhancing axon growth and method of treating neurodegenerative diseases and spinal muscular atrophy | |
EA201591108A1 (en) | HUMAN GROWTH HORMON AND ALBUMIN, COMPOSITIONS AND THEIR APPLICATIONS | |
MX2017002476A (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition. | |
PH12015502005B1 (en) | New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy | |
RU2013111675A (en) | RECOMBINANT FC-HYBRID PROTEIN OF THE FIFTH DOMAIN FIBRONECTIN TYPE III DCC | |
NZ629964A (en) | Method for treating inflammation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application lapsed |